<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103490</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-40376</org_study_id>
    <nct_id>NCT03103490</nct_id>
  </id_info>
  <brief_title>18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation</brief_title>
  <official_title>18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the detection of cardiac sarcoidosis or inflammation using
      18F-FSPG PET/MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PET/MRI scans will be performed with a whole-body PET/MR imaging system capable of
      simultaneous PET and MR imaging (SIGNA, GE Healthcare, Milwaukee, WI). Approximately 45-60
      minutes after IV injection of 8 mCi of 18F-FSPG, PET emission scanning and MRI acquisition T1
      weighted scanning will begin imaging both whole body and the heart.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with 18F-FSPG Uptake on PET/MRI Fused Images Indicating Cardiac Involvement of Sarcoidosis</measure>
    <time_frame>an expected average of 2 hours</time_frame>
    <description>Diffuse (widespread), focal (point) and focal-on-diffuse (combination of the two) patterns of 18F-FSPG uptake will be considered to be positive findings indicating cardiac involvement of sarcoidosis or inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Evidence of Whole Body 18F-FSPG Uptake on PET/MRI Fused Images Indicating Extra-cardiac Sarcoidosis</measure>
    <time_frame>an expected average of 2 hours</time_frame>
    <description>The whole-body PET/MRI images will be evaluated for findings of extra-cardiac sarcoidosis. Evidence of 18F-FSPG uptake within the whole body will indicate a positive finding for the presence of extra-cardiac sarcoidosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Sarcoidosis</condition>
  <condition>Myocardial Inflammation</condition>
  <arm_group>
    <arm_group_label>18F-FSPG PET/MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergoing 18F-FSPG PET/MRI scan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-FSPG PET/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients undergoing 18F-FSPG PET/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FSPG</intervention_name>
    <description>Patients will receive 8mCi of 18F-FSPG and undergo PET/MRI or PET/CT imaging to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation and the utility of PET/MR to detect these conditions.</description>
    <arm_group_label>18F-FSPG PET/CT</arm_group_label>
    <arm_group_label>18F-FSPG PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is â‰¥ 18 years old at the time of the scan

          -  Patient with known or suspected cardiac sarcoidosis.

          -  Patient is capable of complying with study procedures

          -  Patient can remain still for duration of imaging procedure

        Exclusion Criteria:

          -  Patient is pregnant or nursing

          -  Metallic implants (contraindicated for MRI)

          -  History of renal insufficiency (only for MRI contrast administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Otte, DPT</last_name>
    <phone>(650) 736-4183</phone>
    <email>anotte@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Otte, DPT</last_name>
      <phone>650-736-4183</phone>
      <email>anotte@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Risa Jiron</last_name>
      <phone>650-736-1598</phone>
      <email>rjiron@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>PET/MR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

